BrainJuicer Group PLC (AIM: BJU)

("BrainJuicer" or "the Company")

Transaction in Own Shares and Director Dealing

BrainJuicer, the international market research agency, announces that it yesterday purchased 422,762 ordinary shares into Treasury pursuant to the Company's share buy-back announced on 31 March 2016 (the "Buyback"), at a price of 332.5 pence per share.

John Kearon, Chief Executive Officer, yesterday sold a total of 500,000 shares at a price of 332.5 pence per share.

As a result of the above transactions: (1) the Company holds 932,030 ordinary shares in Treasury, and its total number of ordinary shares with voting rights has declined to 12,291,732; and (2) John Kearon is beneficially interested in 3,359,996 ordinary shares, representing 27.34% of the voting rights of the Company.

As noted in the announcement on 31 March, any shareholders wishing to participate in the Buyback should contact the Company's broker Canaccord Genuity Limited.  The Buyback will be undertaken until the earlier of all 1 million ordinary shares being repurchased and the Company's 2016 Annual General Meeting on 6 May 2016.  

The Company further notes that the executive director LTIP performance measures relating to earnings per share will be adjusted for the shares purchased under the Buyback, so that the earnings per share performance targets are no easier to achieve than they would have been had the Buyback not taken place.

The Company will make further announcements in due course following the completion of any further purchases pursuant to the Buyback.

Related Party Transaction

As the vendor of the 422,762 ordinary shares purchased by the Company, at 332.5 pence per share, is John Kearon, Chief Executive Officer of the Company, this transaction is a related party transaction pursuant to AIM Rule 13. The directors of the Company, having consulted with the Company's nominated adviser, Canaccord Genuity Limited, consider that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.

For further information, please contact: